West M - Search Results

1

Agalsidase alfa and kidney dysfunction in Fabry disease.

West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. West M, et al. J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8. J Am Soc Nephrol. 2009. PMID: 19357250 Free PMC article.

2

Diagnosis and management of kidney involvement in Fabry disease.

Warnock DG, West ML. Warnock DG, et al. Adv Chronic Kidney Dis. 2006 Apr;13(2):138-47. doi: 10.1053/j.ackd.2006.01.013. Adv Chronic Kidney Dis. 2006. PMID: 16580615 Review.

3

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.

Clarke JT, West ML, Bultas J, Schiffmann R. Clarke JT, et al. Genet Med. 2007 Aug;9(8):504-9. doi: 10.1097/GIM.0b013e318133fb1b. Genet Med. 2007. PMID: 17700388 Free article. Clinical Trial.

4

Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.

Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, Germain DP, Laframboise R, Melançon SB, Stockley T, Clarke JT, Drouin R. Auray-Blais C, et al. Mol Genet Metab. 2008 Mar;93(3):331-40. doi: 10.1016/j.ymgme.2007.10.001. Epub 2007 Nov 26. Mol Genet Metab. 2008. PMID: 18023222

5

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Feriozzi S, et al. Among authors: west m. Am J Nephrol. 2009;29(5):353-61. doi: 10.1159/000168482. Epub 2008 Oct 31. Am J Nephrol. 2009. PMID: 18974635 Free article. Review.

6

A validated disease severity scoring system for Fabry disease.

Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. Giannini EH, et al. Among authors: west m. Mol Genet Metab. 2010 Mar;99(3):283-90. doi: 10.1016/j.ymgme.2009.10.178. Epub 2009 Oct 30. Mol Genet Metab. 2010. PMID: 19951842

7

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT; Fabry Outcome Survey investigators. Mehta A, et al. Lancet. 2009 Dec 12;374(9706):1986-96. doi: 10.1016/S0140-6736(09)61493-8. Lancet. 2009. PMID: 19959221

8

Enzyme replacement therapy and Fabry nephropathy.

Warnock DG, Daina E, Remuzzi G, West M. Warnock DG, et al. Among authors: west m. Clin J Am Soc Nephrol. 2010 Feb;5(2):371-8. doi: 10.2215/CJN.06900909. Epub 2009 Dec 10. Clin J Am Soc Nephrol. 2010. PMID: 20007680

9

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative.

Sirrs S, Clarke JT, Bichet DG, Casey R, Lemoine K, Flowerdew G, Sinasac DS, West ML. Sirrs S, et al. Among authors: west ml. Mol Genet Metab. 2010 Apr;99(4):367-73. doi: 10.1016/j.ymgme.2009.11.001. Epub 2009 Nov 16. Mol Genet Metab. 2010. PMID: 20022777 Clinical Trial.

10

How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer JM, Zhang XK, Gagnon R. Auray-Blais C, et al. Among authors: west ml. Clin Chim Acta. 2010 Dec 14;411(23-24):1906-14. doi: 10.1016/j.cca.2010.07.038. Epub 2010 Aug 14. Clin Chim Acta. 2010. PMID: 20716442

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,316 results

Search Page

Filters